

FIG 1




FIG. 2A





FIG. 2B



Treatment group:

- Placebo (n=102)
- Anifrolumab 300 mg (n=99)
- ▲— Anifrolumab 1000 mg (n=104)

IFNGS, type I interferon gene signature; n, number of nonmissing values; SE, standard error

FIG. 3A

Disease activity measure		Placebo (n=66)	Anifrolumab 300mg (n=84)	Anifrolumab 1000mg (n=73)
SLEDAI-2K score	Week 52, mean	5.9	4.3	3.8
	Week 60, mean	5.8	5.0	4.1
	Mean change (SD) ^a	-0.1 (2.4)	0.7 (3.5)	0.3 (2.3)
BILAG-2004 score	Week 52, mean	8.3	6.0	5.9
	Week 60, mean	9.1	8.5	6.6
	Mean change (SD) ^a	0.8 (3.8)	2.4 (6.7)	0.7 (5.3)
CLASI activity score	Week 52, mean	3.5	1.9	1.8
	Week 60, mean	4.0	2.4	2.2
	Mean change (SD) ^a	0.5 (2.3)	0.4 (1.9)	0.4 (2.0)
MDGA score	Week 52, mean	0.73	0.58	0.65
	Week 60, mean	0.73	0.75	0.73
	Mean change (SD) ^a	0 (0.31)	0.17 (0.54)	0.08 (0.39)
Active joint count	Week 52, mean	2.8	2.3	1.7
	Week 60, mean	3.2	3.3	2.4
	Mean change (SD) ^a	0.4 (3.9)	1.0 (4.9)	0.7 (3.5)

FIG. 3B

	Placebo (n=67)	Anifrolumab 300mg (n=85)	Anifrolumab 1000mg (n=75)
Patients with ≥ 1 flare, n (%)	2 (3.0)	15 (17.6)	7 (8.2)
Number of flares per patient, n (%)			
0	65 (97.0)	70 (82.4)	68 (90.7)
1	1 (1.5)	14 (16.5)	7 (9.3)
2	1 (1.5)	1 (1.2)	0 (0)
Annualized flare rate per patient, mean (SD)	0.292 (1.771)	1.188 (2.687)	0.585 (1.841)

SD, standard deviation

FIG 4




FIG. 5

Characteristics	Placebo (n=366)	Anifrolumab 300 mg (n=366)
Age, mean (SD), years	41.0 (11.9)	42.6 (12.0)
Female, n (%)	341 (93.2)	333 (92.5)
Race, n (%)		
White	244 (66.7)	235 (65.3)
Black	35 (9.6)	41 (11.4)
Asian	48 (13.1)	46 (12.8)
Other	31 (8.5)	30 (8.3)
Time from initial SLE diagnosis to randomization, median (range), months	78.5 (4–503)	91.0 (0–555)
BILAG-2004, n (%)		
≥1 A item	179 (48.9)	174 (48.3)
No A items and ≥2 B items	162 (44.3)	170 (47.2)
SLEDAI-2K		
Global score, mean (SD)	11.5 (3.7)	11.4 (3.8)
Score ≥10, n (%)	260 (71.0)	251 (69.7)
PGA score, mean (SD)	1.8 (0.4)	1.8 (0.4)
CLASI activity score, mean (SD)	7.8 (7.2)	8.4 (7.6)
SDI global score, mean (SD)	0.6 (0.9)	0.6 (1.0)
Number of swollen joints, mean (SD)	7.2 (5.7)	6.8 (5.8)
Number of tender joints, mean (SD)	10.8 (7.5)	10.3 (7.4)
Baseline treatment for SLE, n (%)		
OCS ^a	304 (83.1)	291 (80.8)
<10 mg/day	181 (49.5)	351 (48.3)
≥10 mg/day	185 (50.5)	375 (51.7)
Antimalarial	267 (73.0)	243 (67.5)
Immunosuppressant ^b	177 (48.4)	173 (48.1)

FIG. 6A




FIG. 6B





FIG. 6C



- Placebo (n=366)
- Anifrolumab 300 mg (n=360)
- A
- B
- C
- D
- E

FIG. 7




FIG. 8




FIG. 9A




FIG. 9B





FIG. 9C



■ Anifrolumab 300 mg ■ Placebo

Data pooled from TULIP-1 and TULIP-2 trials.

FIG. 10A




FIG. 10B




FIG. 11




FIG. 12





FIG. 12 is a heatmap showing the mucocutaneous organ domain involvement at baseline and over time (Study week) for patients in the Placebo (n=312) and Anifrolumab 300 mg (n=315) groups. The heatmap is divided into Baseline A and Baseline B sections. The color scale indicates the level of involvement: A (dark grey), B (medium grey), C (light grey), and D (white). The x-axis represents Study week (0 to 52). The y-axis represents the organ domain involvement at baseline. The legend indicates that dark grey represents 'No Data'.

FIG. 13



Number of score shifts 1 (A to B or B to C) 2 (A to C or B to D) 3 (A to D)
Placebo (n=366) Anifrolumab 300 mg (n=360)

FIG. 14




FIG. 15




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 19A




FIG. 19B




FIG. 19C




FIG. 20




FIG. 21A




FIG. 21B




FIG. 22A




FIG. 22B




FIG. 22C




FIG. 23A




FIG. 23B




FIG. 24A




FIG. 24B

IFNGS High SLE Subjects




FIG. 25A




FIG. 25B




FIG. 26A




FIG. 26B




FIG. 27A




FIG. 27B




FIG. 28




FIG. 29A




FIG. 29B




FIG. 29C




FIG. 30A




FIG. 30B





FIG. 31






FIG. 32A




FIG. 32B

FIG. 33A




FIG. 33B




FIG. 33C




FIG. 34A




FIG. 34B




FIG. 34C




FIG. 34D




FIG. 35

